Cargando…
Effects of Hypoxia and Transferrin on Toxicity and DNA Binding of Ruthenium Antitumor Agents in Hela Cells
Nuclear DNA binding and inhibition of growth of HeLa cells in culture were determined after 24 h incubation with the ruthenium anticancer agents cis-[Cl(2)(NH(3))(4)Ru]Cl (CCR) and (ImH)trans-[(Im)(2)Cl(4)Ru] (ICR) as a function of [Ru], Po(2), and added transferrin. Consistent with the “activation-...
Autores principales: | Frasca, D., Ciampa, J., Emerson, J., Umans, R. S., Clarke, M. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365025/ https://www.ncbi.nlm.nih.gov/pubmed/18475755 http://dx.doi.org/10.1155/MBD.1996.197 |
Ejemplares similares
-
p-Cymene Complexes of Ruthenium(II) as Antitumor Agents
por: Pujante-Galián, María Angeles, et al.
Publicado: (2020) -
Controversial Role of Transferrin in the Transport of Ruthenium Anticancer Drugs
por: Levina, Aviva, et al.
Publicado: (2022) -
Binding of Antitumor Ruthenium(III) Complexes to Plasma Proteins
por: Messori, L., et al.
Publicado: (2000) -
Transferrin-modified liposomes triggered with ultrasound to treat HeLa cells
por: AlSawaftah, Nour M., et al.
Publicado: (2021) -
New Heteroleptic Ruthenium(II) Complexes with Sulfamethoxypyridazine and Diimines as Potential Antitumor Agents
por: de Melo, Ariane C.C., et al.
Publicado: (2019)